PeerVoice Heart & Lung Video PeerVoice

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Visit https://www.peervoice.com/UPK860 to view the entire programme with slides. After completing “Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care”, participants will be able to: Explain the rationale for screening asymptomatic patients for lung cancer based on identified eligibility criteria; Outline practical tips for primary care to screen and monitor appropriate patients for lung cancer, in order to facilitate early identification; Discuss when to investigate lung cancer in symptomatic patients; and Apply effective strategies to optimize referral into the diagnostic assessment clinic.

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Visit https://www.peervoice.com/RVW860 to view the entire programme with slides. After completing “Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care”, participants will be able to: Discuss the pathogenic mechanisms in severe eosinophilic asthma and the role of biomarkers in informing treatment; Describe the role of biologics in improving patient outcomes and their impact on background medication use; and Outline the most recent real-world evidence with biologics for severe eosinophilic asthma and its clinical implications for patient management.

Visit https://www.peervoice.com/QJJ860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block”, participants will be able to: Explain the role of combination angiotensin receptor neprilysin inhibitor therapy (ARNI) as a component of guideline-directed medical therapy (GDMT) in heart failure (HF); Formulate practical strategies for incorporating renin-angiotensin-aldosterone system (RAAS) inhibition, including ARNI, in management plans for patients with HF; and Apply recommended monitoring and management strategies to optimise the safety and efficacy of RAAS inhibition, including ARNI, in HF.

Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.